News

Filter

Current filters:

Prevnar

1 to 9 of 58 results

Expanded use for Pfizer’s Prevnar 13

03-01-2012

Following a previous US Food and Drug Administration advisory panel recommendation (The Pharma Letter…

North AmericaPfizerPharmaceuticalPrevnarRegulationVaccines

US FDA backs SC form of B-MS Orencia; extends review of Pfizer’s Prevnar 13

01-08-2011

The US Food and Drug Administration has approved a subcutaneous (SC) formulation of drug major Bristol-Myers…

Anti-Arthritics/RheumaticsBristol-Myers SquibbNorth AmericaOrenciaPfizerPharmaceuticalPrevnarRegulationVaccines

Despite boost to Australia mental health funding, latest schizophrenia drug still blocked

11-05-2011

As part of its latest budget announcement, Australia’s federal government has allocated A$2.2 billion…

HealthcareNeurologicalPharmaceuticalPoliticsPrevnarPricingVaccines

Pfizer’s Prevnar 13 meets all endpoints in pivotal Ph III trials on over 50s

10-05-2011

Global drugs behemoth Pfizer (NYSE: PFE) says that the data from its two pivotal Phase III immunogenicity…

PfizerPharmaceuticalPrevnarResearchRespiratory and PulmonaryVaccines

Melanoma drug market to see CAGR of 16.8% to reach $1.42 billion by 2017; pneumo- and meningococcal vaccines forecast

31-01-2011

The worldwide market for melanoma therapeutics was valued at $351 million in 2009 and is forecast to…

GlobalMarkets & MarketingOncologyPfizerPharmaceuticalPrevnarVaccines

1 to 9 of 58 results

COMPANY SPOTLIGHT

Menarini

Back to top